Posts

nTIDE October 2023 Jobs Report: People with disabilitie...

East Hanover, NJ – November 3, 2023 – Experts reported little change in October’...

Illinois Tech grows research footprint, securing prime ...

CHICAGO—November 3, 2023—Illinois Institute of Technology (Illinois Tech) has le...

Physicists ask: Can we make a particle collider more en...

Ever since the discovery of the Higgs boson in 2012, physicists have wanted to b...

Management of recurrent gastrointestinal cancer with ri...

“The patient was managed with ripretinib and surgical resection of progressing l...

FDA Advisors Greenlight First CRISPR-Based Therapy with...

FDA advisers have expressed contentment with CRISPR Therapeutics and Vertex Phar...

C4 Therapeutics Abandons Cancer Program and Awaits Paym...

C4 Therapeutics has made the decision to discontinue the development of one of i...

40% of patients respond to Deciphera’s tumor-fighting o...

Over three years following the initial approval of a pharmaceutical by Deciphera...

Camidanlumab tesirine by ADC Therapeutics for Myelodysp...

Camidanlumab tesirine is under clinical development by ADC Therapeutics and curr...

AB-1003 by Asklepios BioPharmaceutical for Limb-Girdle ...

AB-1003 is under clinical development by Asklepios BioPharmaceutical and current...

Darovasertib by Ideaya Biosciences for Colorectal Cance...

Darovasertib is under clinical development by Ideaya Biosciences and currently i...

GRWD-5769 by Grey Wolf Therapeutics for Solid Tumor: Li...

GRWD-5769 is under clinical development by Grey Wolf Therapeutics and currently ...

APVO-436 by Aptevo Therapeutics for Myelodysplastic Syn...

APVO-436 is under clinical development by Aptevo Therapeutics and currently in P...

PRT-811 by Prelude Therapeutics for CNS Lymphoma: Likel...

PRT-811 is under clinical development by Prelude Therapeutics and currently in P...

Bezuclastinib by Cogent Biosciences for Systemic Mastoc...

Bezuclastinib is under clinical development by Cogent Biosciences and currently ...

Rituximab biosimilar by Celltrion for Waldenstrom Macro...

Rituximab biosimilar is under clinical development by Celltrion and currently in...

Gebasaxturev by Merck for Oral Cavity (Mouth) Cancer: L...

Gebasaxturev is under clinical development by Merck and currently in Phase II fo...